Benefit and Harm of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in COVID-19 Patients: A Review Protocol of Systematic Review and Meta-Analysis
Not Applicable
Recruiting
- Conditions
- There is a controversial debate regarding how to treat cardiovascular disease in COVID-19 confirmed patients. Ones documented that ACE inhibitor may increase risk of fatal COVID-19 by serving entry site for this virus, on contrary ones documented that ACEi and/or ARB may be beneficial for Acute Lung Injury and cardiovascular protection.
- Registration Number
- JPRN-UMIN000041430
- Lead Sponsor
- Faculty of Medicine, Universitas Airlangga
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
The exclusion criteria are (1) non-English articles; (2) review, case-control studies, case reports, and case series; (3) studies without full-text articles; (4) studies that do not contain primary data in their published articles; and (5) unpublished records such as conference papers, theses, and patents.
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method cardiovascular mortality, all-cause mortality, severity, ARDS, need for ICU care, mechanical ventilation, hospitalization, cardiovascular injury, myocarditis, myocardial infarction, stroke, and heart failure
- Secondary Outcome Measures
Name Time Method individual percentage of primary outcomes